4Karl S, John C, Henry D, et al. Guidelines for diagnosis and treatment of chronic heart failure : executive summary [ J ]. European Heart Jour- nal, 2005, 26(6) : 1115 -1140.
5Burger A J, Aronson D, Horton D P, et al. Comparison of the effects of dobutamine and nesiritide ( B - type natriuretic peptide) on ventricular ectopy in acutely decompensated ischemicversus nonischemic eardiomy- opathy[ J ]. Am J Cardiol, 2003, 91 ( 11 ) : 1370 - 1372.
6Antoniades C, Tousoulis D, Koumallos N, et al. Levosimendan: beyond its simple inotropic effect in heart failure [ J ]. Pharmacol Ther, 2007, 114 (2): 184-197.
7Antila S, Sundbcrg S, Lehtonen I A. Clinical pharmacology of levosi- mendan [J]. Clin Pharmacokinet, 2007, 46(7) : 535 -552.
8Ikonomidis I, Parissis J T, Paraskevaidis L, et al. Effects of levosimen- dan oil coronary artery flow and cardiac perform ance in patients with ad- vanced heart failure[J]. Eur J Heart Fail, 2007, 9 (12) : 1172 - 1177.
9Pataricza J, Krassoi I, Hohn J, et al. Functional role of potassium channels in the vasodilsting mechanism of levosimendan in porcine isola- ted coronary artery[J]. Cardiovasc Drugs Ther, 2003, 17(2) : 115 - 121.
10Toiler W G. Stranz C. Levosimendan, a new inotropic and vasodilator agent[ J]. Anesthesiol, 2006, 104 : 556 - 569.
